Challenger significantly reduces stakes in Telix Pharmaceuticals and Qube Holdings

On September 1, 2025, Challenger Limited announced it had ceased to be a substantial holder in Telix Pharmaceuticals Ltd as of August 28, 2025. This followed a previous notice given on August 25, 2025. The total number of Telix Pharmaceuticals securities affected by these changes was -585,347, reflecting a series of sell and buy transactions between August 21 and August 28, 2025.

In a related move, Challenger also reported a change in its interests in Qube Holdings Limited, reducing its voting power from 7.18% to 6.15%. This change, effective August 28, 2025, represents a decrease of 18,229,162 Ordinary Fully Paid shares since the previous notice on February 25, 2025. These adjustments reflect Challenger's dynamic portfolio management strategies across various entities.